Valve-in-valve TAVR is a minimally invasive heart procedure where a new replacement valve is placed inside an older biological valve that has worn out. Instead of open-heart surgery to remove the failed valve, a catheter delivers a new valve through a blood vessel and wedges it firmly inside the old one, pushing the deteriorated leaflets out of the way. It’s a second chance for patients whose first replacement valve has reached the end of its lifespan.
Why Biological Valves Eventually Fail
Biological (bioprosthetic) heart valves, made from animal tissue, don’t last forever. Over 10 to 20 years, the leaflets stiffen, calcify, or tear. This is called structural valve deterioration, and it’s the most common reason a biological valve needs to be replaced. At the five-year mark, roughly 4% of surgical bioprosthetic valves show signs of structural deterioration. That number climbs as the years go on.
The failure can show up in two ways. The valve may become stenotic, meaning it stiffens and won’t open fully, forcing the heart to work harder to push blood through a narrower opening. Or the leaflets may stop closing properly, allowing blood to leak backward (regurgitation). Some patients develop both problems at once. Less commonly, a valve can fail due to issues that aren’t about the tissue itself: blood clots forming on the leaflets, infection, tissue overgrowth around the valve, or a valve that was slightly too small or poorly positioned from the start.
How the Procedure Works
The concept is straightforward. A compressed replacement valve, mounted on a balloon or a self-expanding frame, travels through a catheter inserted in the femoral artery (in the groin) and is guided up to the heart. Once positioned inside the old surgical valve, the new valve expands. It locks into place by pressing against the rigid ring of the original valve, and the old leaflets get pinned flat against the walls. The new valve immediately takes over the job of regulating blood flow.
The entire procedure is done under imaging guidance, typically with a combination of X-ray fluoroscopy and ultrasound. There’s no need to stop the heart or use a heart-lung bypass machine. Most patients receive sedation or general anesthesia, but the chest is never opened.
Pre-Procedural Planning and CT Imaging
Getting precise measurements before the procedure is critical. A CT scan captures detailed images of the heart during both contraction and relaxation phases. The key measurement is the aortic annulus, the ring-shaped structure where the valve sits, at its maximum size during contraction. This tells the team exactly what size replacement valve will fit securely without being too loose or too tight.
The distance from the valve to the coronary arteries also gets measured carefully. The coronary arteries supply blood to the heart muscle and sit just above the aortic valve. If the new valve is too tall or if the old valve’s leaflets get pushed outward too far, they can block one of these arteries. This is the most dangerous potential complication of the procedure, and accurate imaging is the primary way to prevent it.
Coronary Obstruction: The Main Risk
Coronary obstruction occurs in about 2% to 6% of valve-in-valve cases, a relatively low number that carries outsized consequences. When it happens, the 30-day death rate is 40% to 50%. This is why pre-procedural CT planning focuses so heavily on predicting whether the new valve will crowd the coronary openings. Specifically, if the projected distance between the new valve frame and the coronary artery is less than 4 millimeters, the risk of obstruction rises significantly.
For patients identified as high risk, the care team can take preventive steps during the procedure, such as placing a protective stent in the coronary artery or using techniques to split the old valve leaflets before deploying the new one.
The Small Valve Problem
One inherent limitation of nesting a valve inside a valve is that the new one has to fit within the frame of the old one. This means the opening available for blood flow is smaller than it would be with a standalone surgical replacement. In some patients, particularly those with smaller body frames or those who received a small surgical valve originally, this can lead to prosthesis-patient mismatch. The valve works, but its opening is too small relative to the patient’s body size.
When mismatch is severe, the heart has to pump harder to force blood through the restricted opening. Over time, this prevents the thickened heart muscle from recovering the way it should after valve replacement, and it raises the risk of heart failure hospitalization. Despite this limitation, device success rates in patients with small aortic anatomy remain excellent. A Japanese nationwide registry reported procedural success of 98.2% even in patients with small valve rings, comparable to the 98.9% success in patients with larger anatomy.
Compared to Repeat Open-Heart Surgery
Before valve-in-valve TAVR existed, a second open-heart surgery (redo surgical aortic valve replacement) was the only option for a failed biological valve. That operation carries significant risk because it involves cutting through scar tissue from the first surgery, going back on the heart-lung machine, and enduring a longer, more complex recovery.
A propensity-matched study comparing the two approaches found that 30-day mortality was 7.5 percentage points lower with valve-in-valve TAVR than with repeat surgery. At five years, 76.8% of valve-in-valve patients were alive compared to 66.8% of those who had redo surgery. The differences in bleeding were even more dramatic: only 17.6% of valve-in-valve patients needed blood transfusions compared to 81.7% of surgical patients. Pacemaker implantation rates and hospital stays were also lower with the catheter-based approach.
Current ACC/AHA guidelines rate valve-in-valve TAVR as a reasonable option (Class 2a recommendation) for patients with bioprosthetic leaflet degeneration, particularly those at high or prohibitive surgical risk. For younger, lower-risk patients, the decision between repeat surgery and valve-in-valve TAVR involves weighing the larger valve opening that surgery provides against the lower short-term risk and faster recovery of the catheter approach.
Recovery Timeline
Recovery is one of the biggest practical advantages over repeat surgery. Most patients leave the hospital within one to two days. Light daily activities can resume within days of the procedure, though heavy lifting and strenuous exercise should wait at least a week. Compare that to redo open-heart surgery, which typically requires a week or more in the hospital and weeks to months of restricted activity while the breastbone heals.
How Long Valve-in-Valve Results Last
Long-term durability data is still accumulating, but early results are encouraging. The PARTNER-1 trial showed no evidence of structural valve deterioration at five years for transcatheter valves. A separate study following 152 patients who received transcatheter valves between 2007 and 2011 performed ultrasound follow-up at an average of 6.3 years in those surviving beyond five years. No cases of structural deterioration were found, and only 3.3% needed a repeat procedure, mostly for minor leaks around the valve rather than valve failure itself.
Pooled data from two large randomized trials found that transcatheter valves using a self-expanding design had lower rates of valve dysfunction at five years compared to surgical valves (7.8% vs. 14.2%). Structural deterioration specifically occurred in 2.2% of transcatheter valves versus 4.4% of surgical valves over that period. When valve dysfunction does develop, regardless of approach, it raises the risk of death and heart failure hospitalization by roughly 1.5 times at five years.
These durability numbers come from transcatheter valves placed in native (original) aortic valves rather than inside old surgical valves specifically. Durability of valve-in-valve implants may differ, particularly in patients with small valve frames where higher residual pressure gradients could accelerate wear. Ongoing registries are tracking these patients to build a clearer long-term picture.